BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34383091)

  • 1. Lymphocyte-to-C-Reactive Protein Ratio as a Novel Marker for Predicting Oncological Outcomes in Patients with Esophageal Cancer.
    Takeuchi M; Kawakubo H; Hoshino S; Matsuda S; Mayanagi S; Irino T; Fukuda K; Nakamura R; Wada N; Kitagawa Y
    World J Surg; 2021 Nov; 45(11):3370-3377. PubMed ID: 34383091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of the preoperative lymphocyte C-reactive protein ratio in esophageal cancer patients.
    Yamamoto A; Toiyama Y; Okugawa Y; Ichikawa T; Imaoka H; Yasuda H; Fujikawa H; Okita Y; Yokoe T; Ohi M
    Surg Today; 2021 May; 51(5):745-755. PubMed ID: 33130991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Could lymphocyte to C-reactive protein ratio predict the prognosis in patients with gastric cancer?
    Angin YS; Yildirim M; Dasiran F; Okan I
    ANZ J Surg; 2021 Jul; 91(7-8):1521-1527. PubMed ID: 33956378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical impacts of lymphocyte-to-C-reactive protein ratio for esophageal cancer patients who receive curative treatment.
    Aoyama T; Nagasawa S; Nakazono M; Segami K; Tamagawa H; Tamagawa A; Hara K; Oshima T; Yukawa N; Masuda M; Rino Y
    J Cancer Res Ther; 2023; 19(3):556-561. PubMed ID: 37470574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of Neutrophil to Lymphocyte Ratio at Recurrence for Predicting Long-Term Outcomes in Patients with Recurrent Esophageal Squamous Cell Carcinoma.
    Hoshino S; Takeuchi M; Kawakubo H; Matsuda S; Mayanagi S; Irino T; Fukuda K; Nakamura R; Wada N; Kitagawa Y
    Ann Surg Oncol; 2021 Jun; 28(6):3001-3008. PubMed ID: 33689078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative lymphocyte to C-reactive protein ratio as a new prognostic indicator in patients with resectable gallbladder cancer.
    Yao WY; Wu XS; Liu SL; Wu ZY; Dong P; Gong W
    Hepatobiliary Pancreat Dis Int; 2022 Jun; 21(3):267-272. PubMed ID: 34507896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cumulative perioperative lymphocyte/C-reactive protein ratio as a predictor of the long-term outcomes of patients with colorectal cancer.
    Okugawa Y; Toiyama Y; Fujikawa H; Kawamura M; Yasuda H; Yokoe T; Mochiki I; Okita Y; Ohi M; Nakatani K
    Surg Today; 2021 Dec; 51(12):1906-1917. PubMed ID: 33954875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between the Lymphocyte-to-C-Reactive Protein Ratio and Survival Outcomes in Cancer Patients with GLIM-Defined Malnutrition: A Multicenter Study.
    Zhang KP; Zhang X; Zhang Q; Ruan GT; Song MM; Xie HL; Zhang HY; Li XR; Yang M; Liu YY; Li QQ; Ge YZ; Liu XY; Lin SQ; Li W; Xu HX; Deng L; Shi HP
    J Nutr Health Aging; 2022; 26(9):847-855. PubMed ID: 36156676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer.
    Okugawa Y; Toiyama Y; Yamamoto A; Shigemori T; Ichikawa T; Yin C; Suzuki A; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; McMillan DC; Kusunoki M
    Clin Nutr; 2020 Apr; 39(4):1209-1217. PubMed ID: 31155370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of lymphocyte to C-reactive protein ratio in predicting survival and postoperative complication for esophago-gastric junction cancer.
    Tsujiura M; Yamamoto A; Imaoka H; Shimura T; Kitajima T; Morimoto Y; Kawamura M; Yasuda H; Okita Y; Yokoe T; Okugawa Y; Ohi M; Toiyama Y
    Surg Oncol; 2022 Sep; 44():101842. PubMed ID: 36081281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer.
    Okugawa Y; Toiyama Y; Yamamoto A; Shigemori T; Ide S; Kitajima T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Yokoe T; Saigusa S; Tanaka K; Shirai Y; Kobayashi M; Ohi M; Araki T; McMillan DC; Miki C; Goel A; Kusunoki M
    Ann Surg; 2020 Aug; 272(2):342-351. PubMed ID: 32675548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of lymphocyte/C-reactive protein ratio on postoperative outcomes in patients with rectal cancer who underwent curative resection.
    Yamamoto T; Fukuda M; Okuchi Y; Oshimo Y; Nishikawa Y; Hisano K; Kawai T; Iguchi K; Okuda Y; Kamimura R; Tanaka E; Terajima H
    Sci Rep; 2022 Oct; 12(1):17136. PubMed ID: 36229569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma.
    Iseda N; Itoh S; Yoshizumi T; Tomiyama T; Morinaga A; Shimagaki T; Wang H; Kurihara T; Toshima T; Nagao Y; Harada N; Oda Y; Mori M
    Int J Clin Oncol; 2021 Oct; 26(10):1890-1900. PubMed ID: 34251555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined analysis of preoperative and postoperative lymphocyte-C-reactive protein ratio precisely predicts outcomes of patients with gastric cancer.
    Miyatani K; Sawata S; Makinoya M; Miyauchi W; Shimizu S; Shishido Y; Matsunaga T; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Saito H; Fujiwara Y
    BMC Cancer; 2022 Jun; 22(1):641. PubMed ID: 35690739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of the Preoperative C-Reactive Protein-to-Albumin Ratio on Survival and Recurrence in Patients With Esophageal Cancer.
    Tamagawa H; Aoyama T; Tamagawa A; Komori K; Maezawa Y; Kano K; Murakawa M; Atsumi Y; Hara K; Kazama K; Numata M; Oshima T; Yukawa N; Masuda M; Rino Y
    Anticancer Res; 2020 Apr; 40(4):2365-2371. PubMed ID: 32234939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of lymphocyte-to-C-reactive protein ratio in patients with gastric cancer after surgery: a multicentre study.
    Cheng CB; Zhang QX; Zhuang LP; Sun JW
    Jpn J Clin Oncol; 2020 Sep; 50(10):1141-1149. PubMed ID: 32564084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of preoperative serum concentrations of interleukin-6 as a prognostic marker in patients with esophageal cancer.
    Maeda Y; Takeuchi H; Matsuda S; Okamura A; Fukuda K; Miyasho T; Nakamura R; Suda K; Wada N; Kawakubo H; Kitagawa Y
    Esophagus; 2020 Jul; 17(3):279-288. PubMed ID: 31845119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative systemic inflammation score (SIS) is superior to neutrophil to lymphocyte ratio (NLR) as a predicting indicator in patients with esophageal squamous cell carcinoma.
    Fu X; Li T; Dai Y; Li J
    BMC Cancer; 2019 Jul; 19(1):721. PubMed ID: 31331297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Preoperative Systemic Immunoinflammatory Measures in Patients with Esophageal Cancer.
    Ishibashi Y; Tsujimoto H; Hiraki S; Kumano I; Yaguchi Y; Horiguchi H; Nomura S; Ito N; Shinto E; Aosasa S; Yamamoto J; Ueno H
    Ann Surg Oncol; 2018 Oct; 25(11):3288-3299. PubMed ID: 30019304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of postoperative inflammatory complications after esophageal cancer surgery based on early changes in the C-reactive protein level in patients who received perioperative steroid therapy and enhanced recovery after surgery care: a retrospective analysis.
    Kano K; Aoyama T; Nakajima T; Maezawa Y; Hayashi T; Yamada T; Sato T; Oshima T; Rino Y; Masuda M; Cho H; Yoshikawa T; Ogata T
    BMC Cancer; 2017 Dec; 17(1):812. PubMed ID: 29202716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.